ArticleBiological trace element research2026
Association of Serum Selenium with Pro-Atherogenic Adhesion Molecules, Inflammatory Cytokines and Carotid Intima-Media Thickness in Patients with Metabolic Syndrome.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium (Se), an essential micronutrient with potent antioxidant properties, may modulate cardiometabolic health through multiple physiological pathways, including redox regulation and the modulation of inflammatory responses. This study aimed to investigate the relationships between serum Se levels and pro-inflammatory cytokines, adhesion molecules, and carotid intima-media thickness (CIMT) as early indicators of endothelial dysfunction in patients with metabolic syndrome (MetS). A total of 191 patients aged 20 to 50 years, diagnosed with MetS, were included in the study. In addition to glucolipid metabolic parameters, serum levels of Se, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and monocyte chemoattractant protein-1 (MCP-1) were assessed. Ultrasonography was applied to measure the CIMT among the participants. The mean serum levels of TNF-α (p-trend = 0.037), MCP-1 (p-trend = 0.005), and VCAM-1 (p-trend = 0.002) revealed decreasing trends with increasing quartiles of serum Se. Similarly, a significant decrease in the mean CIMT was observed in the participants with increasing quartiles of serum Se (p-trend < 0.001). Serum Se levels were inversely correlated with TNF-α (r = -0.24, p < 0.001), MCP-1 (r = -0.30, p < 0.001), VCAM-1 (r = -0.34, p < 0.001), and CIMT (r = -0.47, p < 0.001). In conclusion, we observed significant inverse relationships between serum Se levels and pro-atherogenic and pro-inflammatory biomarkers, as well as the mean CIMT, in patients with MetS. Se supplementation may represent a targeted nutritional strategy for reducing cardiovascular risk in patients with MetS who have low serum Se levels.
Indexed as
Identifiers
40624431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.